Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Recipient : Medicilon
Deal Size : Undisclosed
Deal Type : Collaboration
Medicilon & Hengrui Pharma Deepen Collaboration on ADCs, Small Nucleic Acids, & CGT Drugs
Details : Medicilon & Hengrui will collaborate to focus on the preclinical evaluation of new drug modalities such as ADCs, small molecules, etc & to advance the innovation to compete on an international level.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Recipient : Medicilon
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment
Details : Aitan (rivoceranib), a VEGFR-2 inhibitor, is being investigated with SHR-1210 (camrelizumab) and is already approved in China. The company has resubmitted its NDA to the FDA for unresectable HCC.
Product Name : Aitan
Product Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Hutchmed
Deal Size : Undisclosed
Deal Type : Collaboration
HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer
Details : Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.
Product Name : Sulanda
Product Type : Small molecule
Upfront Cash : Undisclosed
May 15, 2024
Lead Product(s) : Surufatinib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Hutchmed
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fruquintinib,Sintilimab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Hutchmed
Deal Size : Not Applicable
Deal Type : Not Applicable
HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer
Details : Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor, playing a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab for endometrial cancer.
Product Name : Fruzaqla
Product Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2024
Lead Product(s) : Fruquintinib,Sintilimab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Hutchmed
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Mycovia Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).
Product Name : Vivjoa
Product Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2023
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Mycovia Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apatinib (rivoceranib) is a tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 in combination with AiRuiKa (camrelizumab) a humanized mAb targeting the PD-1 receptor, is being investigated fo...
Product Name : Apatinib
Product Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wid...
Product Name : SHR-1210
Product Type : Large molecule
Upfront Cash : Not Applicable
September 10, 2022
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wid...
Product Name : SHR-1210
Product Type : Large molecule
Upfront Cash : Not Applicable
September 07, 2022
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CS1002,CS1003
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : CStone Pharmaceuticals
Deal Size : $200.0 million
Deal Type : Partnership
Details : CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.
Product Name : CS1002
Product Type : Large molecule
Upfront Cash : Undisclosed
November 21, 2021
Lead Product(s) : CS1002,CS1003
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : CStone Pharmaceuticals
Deal Size : $200.0 million
Deal Type : Partnership
Lead Product(s) : Linperlisib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Shanghai Yingli Pharmaceutical
Deal Size : $20.0 million
Deal Type : Agreement
Details : Yingli Pharma will grant Hengrui Medicine joint development rights and exclusive commercialization rights of PI3kδ inhibitor YY-20394 in Greater China.
Product Name : YY-20394
Product Type : Small molecule
Upfront Cash : Undisclosed
February 08, 2021
Lead Product(s) : Linperlisib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Shanghai Yingli Pharmaceutical
Deal Size : $20.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?